Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 803

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients

Open access
Lazarus, Hillard M., Koc, Omer N., Devine, Steven M., Curtin, Peter, Maziarz, Richard T., Holland, H. Kent, Shpall, Elizabeth J., McCarthy, Philip, Atkinson, Kerry, Cooper, Brenda W., Gerson, Stanton L., Laughlin, Mary J., Loberiza, Fausto R., Moseley, Annemarie B., Bacigalupo, Andrea·2005·Biology of Blood and Marrow Transplantation

Abstract

Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support hematopoietic progenitors in vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment and lessen graft-versus-host disease (GVHD); however, the safety and feasibility of this approach needed to be established. In an open-label, multicenter trial, we coadministered culture-expanded MSCs with HLA-identical sibling-matched HSCs in hematologic malignancy patients. Patients received either bone marrow or peripheral blood stem cells as the HSC source. Patients received 1 of 4 study-specified transplant conditioning regimens and methotrexate (days 1, 3, and 6) and cyclosporine as GVHD prophylaxis. On day 0, patients were given culture-expanded MSCs intravenously (1.0-5.0 x 10(6)/kg) 4 hours before infusion of either bone marrow or peripheral blood stem cells. Forty-six patients (median age, 44.5 years; range, 19-61 years) received MSCs and HLA-matched sibling allografts. MSC infusions were well tolerated, without any infusion-related adverse events. The median times to neutrophil (absolute neutrophil count > or = 0.500 x 10(9)/L) and platelet (platelet count > or = 20 x 10(9)/L) engraftment were 14.0 days (range, 11.0-26.0 days) and 20 days (range, 15.0-36.0 days), respectively. Grade II to IV acute GVHD was observed in 13 (28%) of 46 patients. Chronic GVHD was observed in 22 (61%) of 36 patients who survived at least 90 days; it was extensive in 8 patients. Eleven patients (24%) experienced relapse at a median time to progression of 213.5 days (range, 14-688 days). The probability of patients attaining disease- or progression-free survival at 2 years after MSC infusion was 53%. Cotransplantation of HLA-identical sibling culture-expanded MSCs with an HLA-identical sibling HSC transplant is feasible and seems to be safe, without immediate infusional or late MSC-associated toxicities. The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2005.02.001

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. Almeida-Porada, 1999, Cotransplantation of stroma results in enrichment of engraftment and early expression of donor hematopoietic stem cells in utero, Exp Hematol., 27, 1569, 10.1016/S0301-472X(99)00090-9 · doi:10.1016/s0301-472x(99)00090-9
  2. Klyushnenkova, 1998, Human mesenchymal stem cells suppress allogeneic T cell responses in vitro, Blood, 92, 642a
  3. McIntosh, 1999, Suppression of alloreactive T cell responses by human mesenchymal stem cells involves CD8+ cells, Blood, 94, 133a
  4. O’Flaherty, 1995, Bone marrow stromal function from patients after bone marrow transplantation, Bone Marrow Transplant., 15, 207
  5. Stute, 2002, Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant, J Hematother Stem Cell Res., 11, 977, 10.1089/152581602321080646 · doi:10.1089/152581602321080646
  6. Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells) [MPCs], Bone Marrow Transplant., 16, 557
  7. Copelan, 1993, Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2), Semin Oncol., 20, 33
  8. Socié, 2001, Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia, Blood, 98, 3569, 10.1182/blood.V98.13.3569 · doi:10.1182/blood.v98.13.3569
  9. Mills, 1995, BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma, J Clin Oncol., 13, 588, 10.1200/JCO.1995.13.3.588 · doi:10.1200/jco.1995.13.3.588
  10. Blume, 1993, A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission, Blood, 81, 2187, 10.1182/blood.V81.8.2187.2187 · doi:10.1182/blood.v81.8.2187.2187
  11. Bacigalupo, 1999, Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT), Bone Marrow Transplant., 24, 653, 10.1038/sj.bmt.1701953 · doi:10.1038/sj.bmt.1701953
  12. Sullivan, 1981, Chronic graft-versus-host disease in 52 patients, Blood, 57, 267, 10.1182/blood.V57.2.267.267 · doi:10.1182/blood.v57.2.267.267
  13. Bowden, 1991, Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant, Blood, 78, 246, 10.1182/blood.V78.1.246.246 · doi:10.1182/blood.v78.1.246.246
  14. Vigorito, 1998, A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies, Bone Marrow Transplant., 22, 1145, 10.1038/sj.bmt.1701510 · doi:10.1038/sj.bmt.1701510
  15. Schmitz, 1998, Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia, Bone Marrow Transplant., 21, 995, 10.1038/sj.bmt.1701234 · doi:10.1038/sj.bmt.1701234
  16. Blaise, 2000, Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia, J Clin Oncol., 18, 537, 10.1200/JCO.2000.18.3.537 · doi:10.1200/jco.2000.18.3.537
  17. Russell, 1999, Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia, Bone Marrow Transplant., 24, 1177, 10.1038/sj.bmt.1702051 · doi:10.1038/sj.bmt.1702051
  18. Champlin, 2000, Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation, Blood, 95, 3702
  19. Solano, 1998, Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT, Bone Marrow Transplant., 22, 1129, 10.1038/sj.bmt.1701500 · doi:10.1038/sj.bmt.1701500
  20. Heldal, 2000, A randomised study of allogeneic transplantation with stem cells from blood or bone marrow, Bone Marrow Transplant., 25, 1129, 10.1038/sj.bmt.1702422 · doi:10.1038/sj.bmt.1702422
  21. Lazarus, 2001, Culture-expanded human marrow-derived MSCs in clinical hematopoietic stem cell transplantation, Graft, 3, 329
  22. Kumar, 2002, Omission of day +11 methotrexate for graft-versus-host disease prophylaxis after allogeneic BMT increases the risk of severe acute graft-versus-host disease, Bone Marrow Transplant., 30, 161, 10.1038/sj.bmt.1703616 · doi:10.1038/sj.bmt.1703616

Cited by

See all 803

Metadata

Authors
Lazarus, H. M., Koc, O. N., Devine, S. M., Curtin, P., Maziarz, R. T., Holland, H. K., Shpall, E. J., McCarthy, P., Atkinson, K., Cooper, B. W., Gerson, S. L., Laughlin, M. J., Loberiza, F. R., Moseley, A. B., & Bacigalupo, A.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2005-05
Volume
11
Issue
5
Pages
389-398
ISSN
1083-8791 (ISSN-L)
OpenAlex
W2100764718
Cited by
803
References
44
FWCI
34.27
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.